FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2051279483> ?p ?o ?g. }

• W2051279483 endingPage "1526" @default.
• W2051279483 startingPage "1522" @default.
• W2051279483 abstract "Article Abstract Background: Posttraumatic stress disorder (PTSD) is a highly prevalent, disabling illness. Selective serotonin reuptake inhibitors (SSRIs) are considered first-line medication treatment, with sertraline, paroxetine, and fluoxetine being the most studied. More limited but favorable data suggest that citalopram, an SSRI, may also have a role in the treatment of PTSD. Its S-enantiomer escitalopram, which may have faster onset and greater magnitude of effect than citalopram in other conditions, has not yet been investigated in PTSD. Objective: To assess the efficacy, safety, and tolerability of escitalopram in the treatment of PTSD. Method: A 12-week, prospective, open-label trial of escitalopram was conducted from January 2003 through August 2004 in military veterans with PTSD. Escitalopram was initiated at 10 mg daily for 4 weeks, then increased to 20 mg daily for the remainder of the study. Concomitant psychiatric medications were discontinued at least 2 weeks prior to enrollment. The primary outcome variable was the change from baseline to endpoint in global Clinician-Administered PTSD Scale-Symptom version (CAPS-SX) score. Secondary efficacy measures included the Clinical Global Impressions-Severity of Illness (CGI-S) and -Improvement (CGI-I) scales, the Hamilton Rating Scale for Depression (HAM-D), and the Davidson Trauma Scale (DTS). Posttraumatic stress disorder and comorbid diagnoses were established using the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Results: Twenty-four of 25 patients were evaluated for efficacy. The mean global CAPS-SX score decreased from 79.4 (SD = 15.7) at baseline to 61.2 (SD = 24.7) at the end of the study (p = .0002). The CAPS-C avoidance/numbing and CAPS-D hyperarousal subscale scores decreased significantly from baseline to endpoint (CAPS-C, p = .0171; CAPS-D, p = .0001), with trend-level reductions observed in CAPS-B reexperiencing subscale scores (p = .0593). Forty-five percent of patients (9/20) were much or very much improved at the end of the study (CGI-I of 1 or 2). The HAM-D and DTS also significantly improved (p = .0063 and p = .0004, respectively). Mild to moderate gastrointestinal disturbances were the most common side effects. Only 4 patients discontinued early because of adverse effects. Conclusions: This preliminary open-label study suggests that escitalopram is both efficacious and well tolerated in PTSD patients. However, randomized controlled studies are needed to confirm these results and to further define its potential role in the treatment of PTSD." @default.
• W2051279483 created "2016-06-24" @default.
• W2051279483 creator A5006873867 @default.
• W2051279483 creator A5027569058 @default.
• W2051279483 creator A5048495805 @default.
• W2051279483 creator A5055937650 @default.
• W2051279483 creator A5088749034 @default.
• W2051279483 date "2006-10-15" @default.
• W2051279483 modified "2023-10-12" @default.
• W2051279483 title "Open-Label Trial of Escitalopram in the Treatment of Posttraumatic Stress Disorder" @default.
• W2051279483 doi "https://doi.org/10.4088/jcp.v67n1005" @default.
• W2051279483 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17107242" @default.
• W2051279483 hasPublicationYear "2006" @default.
• W2051279483 type Work @default.
• W2051279483 sameAs 2051279483 @default.
• W2051279483 citedByCount "43" @default.
• W2051279483 countsByYear W20512794832012 @default.
• W2051279483 countsByYear W20512794832014 @default.
• W2051279483 countsByYear W20512794832015 @default.
• W2051279483 countsByYear W20512794832016 @default.
• W2051279483 countsByYear W20512794832017 @default.
• W2051279483 countsByYear W20512794832018 @default.
• W2051279483 countsByYear W20512794832019 @default.
• W2051279483 countsByYear W20512794832020 @default.
• W2051279483 countsByYear W20512794832022 @default.
• W2051279483 countsByYear W20512794832023 @default.
• W2051279483 crossrefType "journal-article" @default.
• W2051279483 hasAuthorship W2051279483A5006873867 @default.
• W2051279483 hasAuthorship W2051279483A5027569058 @default.
• W2051279483 hasAuthorship W2051279483A5048495805 @default.
• W2051279483 hasAuthorship W2051279483A5055937650 @default.
• W2051279483 hasAuthorship W2051279483A5088749034 @default.
• W2051279483 hasConcept C118552586 @default.
• W2051279483 hasConcept C126322002 @default.
• W2051279483 hasConcept C15744967 @default.
• W2051279483 hasConcept C170493617 @default.
• W2051279483 hasConcept C197934379 @default.
• W2051279483 hasConcept C2775864247 @default.
• W2051279483 hasConcept C2776134451 @default.
• W2051279483 hasConcept C2776466505 @default.
• W2051279483 hasConcept C2777490545 @default.
• W2051279483 hasConcept C2777669559 @default.
• W2051279483 hasConcept C2777828372 @default.
• W2051279483 hasConcept C2778375690 @default.
• W2051279483 hasConcept C2779177272 @default.
• W2051279483 hasConcept C2779583969 @default.
• W2051279483 hasConcept C2780051608 @default.
• W2051279483 hasConcept C2780733359 @default.
• W2051279483 hasConcept C558461103 @default.
• W2051279483 hasConcept C71924100 @default.
• W2051279483 hasConceptScore W2051279483C118552586 @default.
• W2051279483 hasConceptScore W2051279483C126322002 @default.
• W2051279483 hasConceptScore W2051279483C15744967 @default.
• W2051279483 hasConceptScore W2051279483C170493617 @default.
• W2051279483 hasConceptScore W2051279483C197934379 @default.
• W2051279483 hasConceptScore W2051279483C2775864247 @default.
• W2051279483 hasConceptScore W2051279483C2776134451 @default.
• W2051279483 hasConceptScore W2051279483C2776466505 @default.
• W2051279483 hasConceptScore W2051279483C2777490545 @default.
• W2051279483 hasConceptScore W2051279483C2777669559 @default.
• W2051279483 hasConceptScore W2051279483C2777828372 @default.
• W2051279483 hasConceptScore W2051279483C2778375690 @default.
• W2051279483 hasConceptScore W2051279483C2779177272 @default.
• W2051279483 hasConceptScore W2051279483C2779583969 @default.
• W2051279483 hasConceptScore W2051279483C2780051608 @default.
• W2051279483 hasConceptScore W2051279483C2780733359 @default.
• W2051279483 hasConceptScore W2051279483C558461103 @default.
• W2051279483 hasConceptScore W2051279483C71924100 @default.
• W2051279483 hasIssue "10" @default.
• W2051279483 hasLocation W20512794831 @default.
• W2051279483 hasLocation W20512794832 @default.
• W2051279483 hasOpenAccess W2051279483 @default.
• W2051279483 hasPrimaryLocation W20512794831 @default.
• W2051279483 hasRelatedWork W111163361 @default.
• W2051279483 hasRelatedWork W1507950389 @default.
• W2051279483 hasRelatedWork W1979953349 @default.
• W2051279483 hasRelatedWork W1993034676 @default.
• W2051279483 hasRelatedWork W2009047616 @default.
• W2051279483 hasRelatedWork W2044359142 @default.
• W2051279483 hasRelatedWork W2344780456 @default.
• W2051279483 hasRelatedWork W2348955439 @default.
• W2051279483 hasRelatedWork W2362440058 @default.
• W2051279483 hasRelatedWork W2903934087 @default.
• W2051279483 hasVolume "67" @default.
• W2051279483 isParatext "false" @default.
• W2051279483 isRetracted "false" @default.
• W2051279483 magId "2051279483" @default.
• W2051279483 workType "article" @default.